Overview of Florfenikol

Quick Facts

Property	Description
Active ingredient	Florfenicol (INN)
Form	Injectable Solution, Oral Medicated Feed, Water-soluble Powder
Pharmacological class	Anti-Bacterial Agent, Phenicol Class
Common use	Control of bacterial infectious conditions (veterinary medicine)
Origin	Synthetic, Fluorinated Derivative

What Kind of Antibiotic is Florfenikol?

Florfenikol (Florfenicol) is a synthetic Anti-Bacterial Agent belonging to the Phenicol class of antibiotics, which is used exclusively in veterinary medicine to manage widespread infectious conditions in animal populations. The active ingredient, Florfenicol, is a chemically synthesized compound that acts as a fluorinated derivative of the older antibiotic Thiamphenicol.

This structural alteration is a key differentiating factor: it prevents the enzymatic deactivation that affects related Phenicol antibiotics, allowing Florfenicol to maintain effectiveness against a broad spectrum of bacteria, including strains resistant to Chloramphenicol. This unique resistance profile is a significant advantage over its structural analog. The drug is thus established as a specialized tool for treating conditions such as bovine respiratory disease or enteric septicemia in fish.

Composition and Available Forms of Florfenikol

Florfenikol is manufactured primarily as a single-ingredient product featuring the active ingredient Florfenicol combined with pharmaceutical excipients and a suitable base/vehicle for optimal delivery. For common Injectable Solutions, the active ingredient is dissolved in pharmaceutical solvents like N-Methyl-2-Pyrrolidone (NMP) and Propylene Glycol.

The variety of available dosage forms—including Sterile Injectable Solutions, Oral Medicated Feed preparations, and Water-soluble Powders—is a key feature, demonstrating its adaptability for diverse animal management systems. These diverse presentations ensure flexible and efficient delivery via parenteral (injection) and oral administration routes to large groups of animals within livestock and aquaculture settings.

What is the General Purpose of Florfenikol?

The overarching purpose of Florfenikol is the effective control and resolution of infectious conditions caused by susceptible bacteria by disrupting their growth. Its core mechanism principle involves binding to the bacterial 50S ribosomal subunit, which is the site within the bacteria responsible for protein assembly. By interfering with protein synthesis, Florfenicol achieves a bacteriostatic effect—it arrests the multiplication of the bacterial population, providing the animal’s natural immune system the required time to successfully manage and clear the suppressed bacterial load.

Regulatory References

What side effects are possible with Florfenikol?

Possible Side Effects and Safety Information

The official safety profile for Florfenikol (Florfenicol) is defined by its adverse reaction classifications and constraints documented in government regulatory sources (e.g., FDA, EMA) for its use in veterinary medicine. The majority of documented adverse events are classified based on their frequency and the physiological systems affected.

Frequency and System-Organ Classes

Adverse reactions are predominantly classified as Very Common events, occurring in more than 1 in 10 treated animals. These reactions are mainly observed in two system-organ classes:

Gastrointestinal System Disorders: This includes reactions such as decreased feed consumption (inappetence), transient softening of feces, and diarrhea in treated cattle and swine.
General Disorders and Administration Site Conditions: Following injection, localized reactions are expected, including pain, swelling, and tissue induration at the administration site.

Most gastrointestinal effects are noted in regulatory documents to be transient and reversible.

Serious Reactions and Safety Constraints

While highly uncommon, regulatory summaries note the potential for Very Rare (less than 1 in 10,000) severe adverse reactions, such as anaphylactic shock. Contraindications are also documented, restricting the use of Florfenikol in animals with pre-existing impaired hepatic, cardiac, or renal function and in those with hypersensitivity to the product.

Additionally, the official labeling includes population-specific safety limitations:

Breeding Stock: Safety has not been established for use in male cattle or pigs intended for breeding.
Dairy Production: The product is not approved for use in female dairy cattle 20 months of age or older.

These constraints establish the boundaries of safe application as determined by regulatory authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation provides specific guidance regarding Florfenicol overexposure, detailing observed toxicities in target animals and mandatory actions for accidental human exposure.

Documented Overdose Manifestations

Manifestation Type	Description
Systemic Signs	In target animal species, overdose has been formally linked to decreased body weight or weight gain, decreased food and water consumption, and loose faeces or diarrhoea.
Tissue Damage	Dose-related overexposure is associated with erosive and ulcerative abomasum lesions in cattle. Furthermore, macroscopic intestinal lesions have been observed during post-mortem analysis in calves.

Severe Outcomes and Emergency Actions

Overdose has been associated with fatal outcomes in pre-ruminant calves following repeated, high-dose administration protocols. A specific risk of increased renal toxicity is noted for animals that are severely dehydrated, hypovolaemic, or hypotensive.

When to Seek Immediate Medical Help

In the event of accidental human self-injection or swallowing the product, regulators strictly mandate that the individual seek medical advice immediately and show the package leaflet or label to the physician. If the product is swallowed, the exposed individual must rinse the mouth thoroughly with water and is explicitly instructed to DO NOT induce vomiting. Management of overexposure is limited to symptomatic and supportive treatment, as regulatory texts confirm that no specific antidote is known.

Therapeutic Uses of Florfenikol

What Florfenikol Treats: Main Uses and Benefits

Florfenicol is an antibiotic treatment focused on the resolution of specific and often severe bacterial diseases across key production animal species. Its therapeutic benefit centers on providing broad-spectrum control over the bacterial populations driving acute illness, thereby supporting symptomatic management. The medication is indicated for conditions such as bovine respiratory disease (BRD), interdigital phlegmon (Foot Rot), and severe septicemias in aquaculture.

The drug is relevant across conditions presenting with acute episodes and is commonly used in clinical settings that involve heightened systemic burden. It assists with managing the pronounced symptom cluster of high fever, lethargy, and severe respiratory distress associated with bacterial pneumonia, and supports functional stability during conditions like acute lameness.

“This application is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed.”

In practical settings, Florfenicol is considered relevant for the metaphylactic control of bacterial disease in high-risk groups, such as newly arriving feedlot cattle, and helps manage infectious progression during acute crises in fish populations. It contributes to improved comfort by easing discomfort and supports the patient during difficult episodes by easing distress.

Quick Fact: Primary Therapeutic Focus
Supports Symptomatic Management
Commonly applied in: Acute infectious inflammatory conditions.
Primary Benefit: Supports functional stability and contributes to easing discomfort.

Regulatory References

FDA Freedom of Information Summary

Eligibility and Restrictions for Use

The eligibility profile for Florfenikol is strictly defined by regulatory bodies to ensure animal health standards and protect the human food supply chain. The antibiotic is only authorized for use in specific production animals, including beef and non-lactating dairy cattle, swine, and certain species of freshwater-reared finfish.

Classification

Populations Prohibited or Restricted

Absolute Contraindications

Female dairy cattle 20 months of age or older; calves intended for veal production; adult breeding stock (bulls, rams, boars); animals with known hypersensitivity to the medicine; and animals suffering from impaired hepatic, cardiac, or renal function.

Restrictions and Limitations

Use in pregnant or lactating animals is not established as safe and is generally not recommended. In the absence of safety data, the medicine is not recommended for calves less than four weeks old. Federal regulation restricts the administration of Florfenikol to by or on the order of a licensed veterinarian. For fish, use of medicated feed is limited to a maximum of 10 consecutive days.

This profile governs the lawful application of Florfenikol, excluding sensitive animal classes and ensuring that use is overseen by a licensed professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction profile for Florfenikol, focusing on restrictions and prohibitions as stated in governmental regulatory documents.

Interaction Scope

Category	Description
Medicinal product categories with documented interactions	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Glucocorticoids, Anticoagulant Agents, Other Anti-inflammatory Substances, and Other Veterinary Medicinal Products.
Mechanistic basis of interactions	Interactions are primarily pharmacodynamic (PD) due to the potential for additive or increased adverse effects, and pharmaceutical (physical incompatibility).
Timing-based interaction rules	A treatment-free period of at least 24 hours must be observed between the administration of Florfenikol and other anti-inflammatory substances.

Interaction Classifications (High-Level)

Category	Description
Interaction severity classification	Contraindicated Combinations (for co-administration with other NSAIDs/Glucocorticoids/Anticoagulants) and Major Incompatibility (for physical mixing).
Interaction-context constraints	Constraints are defined by pharmaceutical form (injectable solution mixing rules) and pharmacological class (additive risk with other anti-inflammatory and anticoagulant agents).

Official Interaction Statements

Co-administration is prohibited with Glucocorticoids, other NSAIDs, and Anticoagulant agents.
The product must not be mixed with other veterinary medicinal products in the absence of documented compatibility studies.

Regulatory documents define the product’s interaction structure primarily through pharmacodynamic prohibitions to mitigate the risk of additive toxicity. This profile is further structured by a pharmaceutical incompatibility rule which mandates against physical mixing with any other substance prior to administration.

Mechanism of Action

Florfenicol exerts its primary effect by binding directly to the bacterial 50S ribosomal subunit, acting as an inhibitor of the peptidyl transferase center. This action blocks the formation of peptide bonds and halts the assembly of all essential bacterial proteins, resulting in arrested bacterial proliferation (a bacteriostatic effect). The molecule's unique fluorine atom confers resistance to the inactivation mechanism mediated by Chloramphenicol Acetyltransferases, ensuring the required binding capacity is maintained despite common bacterial defense systems. However, the core mechanism is constrained by bacterial counter-mechanisms, specifically efflux pumps and target-site modification via Ribosomal Methylases, which prevent Florfenicol from reaching the concentration or affinity required to inhibit the peptidyl transferase center, resulting in the continuation of bacterial protein synthesis. Furthermore, in vitro data suggests the drug can modulate host physiological responses by inhibiting the NF-kappaB signaling pathway and reducing the production of certain pro-inflammatory mediators, contributing to the dampening of the inflammatory cascade.

Dosage and Administration Information

Administration Scope: Guidelines for Florfenicol Use

Guidelines for Florfenicol use specify the route, dose, and frequency based on the target animal and the nature of the condition.

Category	Standard Administration Parameters
Route of Administration	Intramuscular (IM) injection, Subcutaneous (SC) injection, or Oral administration (via medicated feed or water).
Dosing Schedule	Cattle (SC): Single dose of 40 mg/kg body weight. Cattle (IM): Two doses of 20 mg/kg body weight each. Finfish (Oral): 10 mg/kg to 15 mg/kg fish biomass per day.
Frequency and Timing	IM Regimen: Two administrations, separated by a 48-hour interval. SC Regimen: Administered as a single dose. Oral Regimen (Finfish): Once daily for 10 consecutive days.
Preparation Requirements	For finfish, the medicated powder must be thoroughly mixed into the complete feed or top-coated onto the feed and administered as the sole ration for the treatment period.

Procedural and Population Constraints

Specific constraints are tied to administration and the product safety profile:

Special Procedural Conditions: For cattle injections, the administration site is restricted: the drug is intended for injection only in the neck. The maximum volume per injection site is also defined (e.g., typically 10 mL for the 300 mg/mL solution).
Age-Group Administration Rules: Use is not authorized in female dairy cattle 20 months of age or older, in animals intended for breeding purposes (e.g., bulls or boars), or in calves designated for veal processing.

The administration protocol defines the method of delivery (parenteral or enteral), the mass-based dosage, and the necessary timing of the course. These requirements collectively structure the use of the drug.

Recent Clinical Evidence

Research evidence / Overview of studies for Florfenikol

This section summarizes the scientific research that has examined Florfenikol, detailing the types of trials that exist and the clinical outcomes that were monitored. The evidence is derived from official sources and is intended to contextualize the evidence landscape, not to serve as clinical guidance.

Evidence for Use in Cattle (Bovine Respiratory Disease and Other Infections)

Research for Bovine Respiratory Disease (BRD) consists mainly of Randomized Controlled Trials (RCTs) and Randomized Field Trials. These studies examined outcomes related to systemic imbalance, including measured clinical outcomes, the status of lung lesions, and patterns in mortality rates. However, some of the comparative evidence is derived from pilot studies or trials that scientific reviewers noted could benefit from larger statistical power. Research for other conditions like Pinkeye is sometimes based on experimentally induced conditions.

Evidence for Use in Aquaculture (Fish Septicemia and Related Conditions)

The evidence for use in finfish is based on Field Efficacy Studies conducted in commercial settings. The primary research outcomes were centered on the control of mortality within the observed populations. Research also monitored susceptible bacterial populations. Data on functional recovery or long-term health status remains limited.

Evidence for Use in Swine Respiratory Disease

The research base includes Efficacy Studies used for the original regulatory approval. These studies examined clinical outcome metrics in swine populations. A key limitation is that the detailed data from the pivotal efficacy trials supporting approval is not always fully available as published public documents.

Long-Term Studies and Follow-Up Duration

The majority of trials utilized follow-up durations that were limited to the immediate post-treatment period. Long-term effects are not fully established in the public domain, as research primarily focuses on short-term changes.

What Research Gaps and Uncertainty Remain

Evidence quality varies, with some comparative evidence derived from trials with modest sample sizes. Research sometimes relies on findings from experimentally induced conditions, which may not fully reflect outcomes in natural field outbreaks. Study results reflect group patterns but not individual predictions for how any single animal will respond.

Key Studies & References FOI Summary for the Supplemental Approval of NADA 141-063 - Nuflor® (florfenicol) Injectable Solution (Cattle)

Frequently Asked Questions (FAQ)

Common questions about Florfenikol (FAQ)

Q: What is the difference between Florfenikol and chloramphenicol?

Florfenikol is chemically similar to the older antibiotic chloramphenicol, acting as a fluorinated derivative. This structural modification was designed to minimize certain toxicity risks. According to regulatory summaries, the difference is believed to minimize the risk of a severe blood disorder known as aplastic anemia, which is highly associated with chloramphenicol. However, changes in blood cell counts are still a potential consideration with Florfenikol.

Q: Is it normal to see a local reaction at the injection site for Florfenikol?

Yes, local reactions at the injection site are considered common and expected adverse events. Official product information classifies pain, swelling, and hardening of the tissue (induration) at the site of administration as 'Very Common' following injection.

Q: How quickly is Florfenikol eliminated from the body?

The rate at which the body eliminates Florfenikol varies depending on the species and the way it is administered. For example, in cattle given an intramuscular injection, the drug’s half-life (the time it takes for the concentration to drop by half) is reported to be around 35.5 hours.

Q: Can exposure to Florfenikol affect human handlers or personnel?

Official labeling states the product is NOT FOR HUMAN USE and warns users to avoid direct contact with skin and eyes, as it can be irritating. Furthermore, due to the presence of a solvent called NMP, official warnings specifically state that pregnant women should wear protective gloves and exercise caution when handling the product.

Q: Does Florfenikol have an effect on gut flora or microbome?

The official safety profile reports common side effects affecting the digestive system, such as transient diarrhea and softening of feces. These effects imply a disruption to the gut flora. Research linked to regulatory review also indicates that Florfenikol has activity against certain bacteria that are part of the normal gut flora.

Q: Is Florfenikol more effective against Gram-positive or Gram-negative bacteria?

Florfenikol is officially classified as a broad-spectrum antibiotic. Regulatory documents confirm its activity against a wide range of both Gram-positive and Gram-negative bacteria. This activity includes the key pathogens responsible for the respiratory and enteric diseases for which the drug is indicated.

Q: How long does it typically take for Florfenikol to start working?

The time required for the drug to reach its maximum concentration in the bloodstream depends on the route of administration. Official pharmacology data indicates that after an intramuscular injection in feeder calves, the peak concentration ( Cmax) is typically reached around 3.3 hours post-injection, which is the point at which maximum antibiotic concentration is achieved.

Q: Does Florfenikol have a risk of bone marrow suppression like chloramphenicol?

The structure of Florfenikol was designed to reduce the risk of certain severe toxicities associated with chloramphenicol. However, regulatory summaries acknowledge that dose-related changes in the blood-forming tissues (hematology) can still occur. Bone marrow hypoplasia has been reported in specific species receiving high or extended doses, indicating the risk is a potential concern, though not generally to the same extent as with chloramphenicol.

Q: What are the signs of a possible allergic reaction to Florfenikol?

The regulatory safety profile notes the potential for anaphylactic shock (a rare, severe allergic reaction) as an adverse event. Official summaries do not provide a detailed list of common or milder allergic symptoms.

Q: Can Florfenikol be safely used in pregnant or nursing animals?

No. Official regulations state that the safety of Florfenikol has not been established for use in breeding animals and is prohibited in certain production animals, such as female dairy cattle 20 months of age or older. Studies associated with regulatory review have also raised concerns regarding adverse effects, such as testicular changes, on the male reproductive system.

Q: Is Florfenikol effective against Mycoplasma infections?

Yes, regulatory documentation and product indications show that Florfenikol is used to treat respiratory infections caused by pathogens including Mycoplasma bovis in certain animal populations. This is sometimes seen with Florfenikol administered as part of a combination product.

Q: Why do some Florfenikol products contain a combination with other drugs?

Combination products (for example, those including an anti-inflammatory drug) are officially marketed to address infections that involve multiple issues. This combination is intended to address the bacterial infection with Florfenikol while also providing the anti-inflammatory action of the other component to manage associated symptoms such as pain, fever, or inflammation.

Q: Is Florfenikol more potent or active than thiamphenicol?

Regulatory summaries frequently describe Florfenikol as possessing a broader spectrum of activity compared to its predecessor, thiamphenicol. A significant benefit is that it maintains its effectiveness against certain strains of bacteria that have developed resistance to thiamphenicol due to its unique chemical structure.

Q: What kind of environmental risks are associated with the use of Florfenikol in aquaculture?

Florfenikol is classified by regulatory authorities as Toxic to aquatic life with long-lasting effects. Official disposal instructions require that the product and related waste materials are not released into surface water or nearby ditches to mitigate this environmental risk.

Q: What specific resistance genes are associated with bacteria resistant to Florfenikol?

Regulatory surveillance and associated research identify that bacterial resistance to Florfenikol is often due to the production of an efflux pump or a change at the target-site where the drug binds. Specific genes, such as mathbffloR, which confers resistance to both Florfenikol and chloramphenicol, are recognized in surveillance reports.

Q: Is Florfenikol ever used alongside other antibiotics for synergistic effects?

The product label contains a pharmaceutical incompatibility rule that mandates against mixing Florfenikol with other veterinary medicinal products without documented studies. Therefore, no official label indications authorize simultaneous use with other antibiotics for synergistic effects.

Q: What is the general safety profile of Florfenikol compared to older antibiotics in its class?

Florfenikol was chemically designed to address the toxic shortcomings of chloramphenicol, particularly the severe risk of aplastic anemia. While not fully exempt from risks, it is not incriminated to the same extent for causing the severe toxicities that are associated with its predecessors.

Q: Can Florfenikol be used for prophylactic (preventative) purposes?

Yes. The official indications for use include prophylaxis in certain high-risk situations. For example, Florfenikol is specifically authorized for the control of respiratory disease in cattle populations known to be at high risk of developing Bovine Respiratory Disease (BRD).

Q: Does Florfenikol have different brand names or generic versions available?

Yes. Regulatory documents from authorities like the FDA list multiple approved New Animal Drug Applications (NADAs) and abbreviated (generic) versions. This means both brand names (such as Nuflor) and generic versions of Florfenikol are officially available on the market.

Q: Is Florfenikol used for any non-bacterial infections?

No. Florfenikol is classified only as an Anti-Bacterial Agent. The official indications for use are strictly limited to the treatment and control of infections caused by susceptible bacteria.

How should Florfenikol be stored and disposed of?

How to Store and Dispose of Florfenicol

Storage and disposal requirements for Florfenicol, an antibiotic primarily for veterinary use, are strictly governed by regulatory labeling to ensure stability and environmental safety.

Storage and Stability Rules

Florfenicol injectable solution must be stored within a temperature range of 2 C to 25 C (36 F to 77 F) and must not be frozen. The product requires protection from light when not in use. Following the first puncture of a multi-dose vial, the solution must be used within 6 months.

Container Restriction: The oral concentrate must not be used or stored in galvanized metal watering systems or containers.
Child Safety: All florfenicol products are labeled KEEP OUT OF REACH OF CHILDREN.

Disposal Instructions

Unused or expired Florfenicol and related waste materials must be disposed of in accordance with local requirements and national regulations. The labeling strictly requires users to avoid release to the environment and prohibits contamination of surface water or ditches.

Florfenikol